0.952
-0.06 (-5.73%)
| Previous Close | 1.01 |
| Open | 0.971 |
| Volume | 63,008 |
| Avg. Volume (3M) | 444,467 |
| Market Cap | 13,044,055 |
| Price / Book | 4.07 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.210 |
| Total Debt/Equity (MRQ) | 4.26% |
| Current Ratio (MRQ) | 2.84 |
| Operating Cash Flow (TTM) | -2.09 M |
| Levered Free Cash Flow (TTM) | -3.52 M |
| Return on Assets (TTM) | -41.71% |
| Return on Equity (TTM) | -375.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Kairos Pharma, Ltd. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.25 |
|
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 57.51% |
| % Held by Institutions | 2.98% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |